Shingles Action Week 2026
New GSK survey finds gaps in shingles awareness and prevention
Financial Results
GlaxoSmithKline Pharmaceuticals Limited announces its Q3FY2026 results
Tata Mumbai Marathon 2026
150+ GSK employees run with a shared commitment to raise awareness on shingles
Press Release
Nashik Facility Achieves Global BSI AMR Kitemark™ Certification
One of the first in India to achieve certification to the international standard for antibiotic manufacturing.
Notices
Revision in GSK India product prices
Implementation of revision in MRPs due to reduction in GST rates
Press Releases
GSK forays into Oncology in India
GSK forays into Oncology in India with Jemperli and Zejula, Bringing Precision Therapies for Gynaecological Cancers
Special Feature
Explore the legacy of a 100-years of trust
A specially curated gallery of our 100-year assets
Scroll to explore
Who we are
As a focused biopharma company, we discover, develop and deliver medicines and vaccines to create value for patients and shareholders. We aim to positively impact the health of 2.5 billion people by the end of the decade.Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.
RESPIRATORY, IMMUNOLOGY AND INFLAMMATION
7m
deaths each year due to lung diseases
ONCOLOGY
~10m
people died from cancer in 2022, making it a leading cause of death worldwide
Life at GSK in India
How we help people thrive
Careers
Culture
Experienced professionals
Early careers
In the spotlight
MEDIA
Press releases and other resources
Investors
Shareholder information
Responsibility
Responsible business